Read by QxMD icon Read

non cirrhotic portal hypertension

Tilman Sauerbruch, Florence Wong
BACKGROUND: The development of cirrhosis with resultant portal hypertension can lead to oesophageal varices at a rate of 7% per annum. Bleeding from varices happens when the portal pressure is ≥12 mm Hg and can threaten life. SUMMARY: Eliminating the aetiology of cirrhosis is a pivotal step to prevent the formation of varices. In patients with established varices, primary prophylaxis with non-selective beta blockers (NSBB) may slow down the progression of varices and prevent the first variceal bleed...
September 13, 2018: Digestion
Du Kong, Wei Wang, Gang Du, Binyao Shi, Zhengchen Jiang, Bin Jin
Background: Although liver retraction using n-butyl-2-cyanoacrylate (NBCA) glue has been applied to laparoscopic upper abdominal surgery in noncirrhotic patients, there is still no consensus on its safety and feasibility for cirrhotic patients. In this study, we aimed to investigate the safety and effectiveness of liver retraction using NBCA glue during laparoscopic splenectomy and azygoportal disconnection (LSD) for gastroesophageal varices and hypersplenism secondary to liver cirrhosis and portal hypertension...
2018: BioMed Research International
Luca Viganò, Fabio Procopio, Antonio Mimmo, Matteo Donadon, Alfonso Terrone, Matteo Cimino, Daniele Del Fabbro, Guido Torzilli
BACKGROUND: The superiority of anatomic resection compared with nonanatomic resection for hepatocellular carcinoma remains a matter of debate. Further, the technique for anatomic resection (dye injection) is difficult to reproduce. Anatomic resection using a compression technique is an easy and reversible procedure based on liver discoloration after ultrasound-guided compression of the tumor-feeding portal tributaries. We compared the oncologic efficacy of compression technique anatomic resection with that of nonanatomic resection...
September 5, 2018: Surgery
Yu-Hsin Hsieh, Hui-Chun Huang, Ching-Chih Chang, Chiao-Lin Chuang, Fa-Yauh Lee, Shao-Jung Hsu, Yi-Hsiang Huang, Ming-Chih Hou, Shou-Dong Lee
Chronic hepatitis is the major cause of liver cirrhosis and portal hypertension. Several factors affect portal pressure, including liver fibrosis, splanchnic vasodilatation and pathological angiogenesis. Nucleos(t)ide analogs (NUCs), the oral antiviral agents, effectively attenuate chronic hepatitis B-related liver cirrhosis and portal hypertension via viral suppression and alleviation of hepatitis. On the other hand, NUCs affect TNF-α, vascular endothelial growth factor (VEGF) and nitric oxide, which participate in fibrogenesis, vasodilatation and angiogenesis...
September 7, 2018: Journal of Pharmacology and Experimental Therapeutics
Clemens Heiser, Bernhard Haller, Maximilian Sohn, Benedikt Hofauer, Andreas Knopf, Tobias Mühling, Jessica Freiherr, Martin Bender, Maximilian Tiller, Anna Schmidt, Wolfgang Schepp, Felix Gundling
INTRODUCTION AND AIM: Olfactory functions are altered to a variable degree by chronic liver disease. Few studies including only small populations of patients emphasized the possibility of hepatic encephalopathy (HE) influencing olfactory nervous tasks. So far, no study has explicitly focused on olfactory function depending on the severity of HE as assessed by objective diagnostic procedures. Thus we performed a study using the "Sniffin' Sticks" test system, critical flicker-fusion frequency (CFF) and clinical West Haven criteria...
August 24, 2018: Annals of Hepatology
Filipe Andrade, Akash Shukla, Christophe Bureau, Marco Senzolo, Louis D'Alteroche, Alexandra Heurgué, Juan-Carlos Garcia-Pagan, Fanny Turon, Frédéric Oberti, Dhiraj Tripathi, Olivier Roux, Pierre-François Ceccaldi, Emmanuelle de Raucourt, Audrey Payancé, Dominique Valla, Aurélie Plessier, Pierre-Emmanuel Rautou
BACKGROUND & AIMS: A total of 15% of patients with idiopathic non-cirrhotic portal hypertension (INCPH) are women of childbearing age. We aimed to determine maternal and fetal outcome of pregnancies occurring in women with INCPH. METHODS: We retrospectively analyzed the charts of women with INCPH followed in the centers of the VALDIG network, having had ≥1 pregnancy during the follow-up of their liver disease. Data are represented as median (interquartile range)...
August 21, 2018: Journal of Hepatology
Virginia C Clark, George Marek, Chen Liu, Amy Collinsworth, Jonathan Shuster, Tracie Kurtz, Joanna Nolte, Mark Brantly
BACKGROUND & AIMS: Alpha-1 antitrypsin deficiency (AATD) is an uncommonly recognized cause of liver disease in adults, with descriptions of its natural history limited to case series and patient-reported data from disease registries. Liver pathology is limited to selected patients or unavailable. Therefore, we aimed to determine the prevalence and severity of liver fibrosis in an adult AATD population who were not known to have cirrhosis, while defining risk factors for fibrosis and testing non-invasive markers of disease...
August 21, 2018: Journal of Hepatology
Maria Guido, Venancio Af Alves, Charles Balabaud, Prithi S Bathal, Paulette Bioulac-Sage, Romano Colombari, James M Crawford, Amar P Dhillon, Linda D Ferrell, Ryan M Gill, Prodromos Hytiroglou, Yasuni Nakanuma, Valerie Paradis, Alberto Quaglia, Pierre E Rautou, Neil D Theise, Swan Thung, Wilson Ms Tsui, Christine Sempoux, Dale Snover, Dirk J van Leuwen
Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare vascular liver disease that has attained a new interest in recent years. It is characterized by clinical signs of portal hypertension in the absence of cirrhosis or severe fibrosis and any known cause of portal hypertension. Since much uncertainty exists about INCPH pathophysiology and no definite diagnostic tests are available, liver biopsy is an essential tool to achieve a definite diagnosis. Unfortunately, the histological diagnosis of INCPH is not always straightforward, since the characteristic lesions are unevenly distributed, vary greatly in their severity and are often very subtle, and not all are necessarily present in a single case...
August 21, 2018: Histopathology
Jia Hao Law, Jarrod Kah Hwee Tan, Kien Yee Michael Wong, Wan Qi Ng, Poh Seng Tan, Glenn Kunnath Bonney, Shridhar Ganpathi Iyer, Madhavan Krishnakumar, Wei Chieh Alfred Kow
BACKGROUND: To compare the presentations and outcomes of anti-HBc seropositive Hepatocellular Carcinoma (HBc-HCC) with anti-HBc seronegative (NHBc-HCC) patients in HBsAg negative Non-HBV Non-HCV (NBNC-HCC) HCC population. METHODS: 515 newly diagnosed HCC patients from January 2011 to September 2016 were retrospectively reviewed. 145 (66.5%) NHBc-HCC and 73 (33.5%) HBc-HCC patients were identified. Patient demographics, disease characteristics, details of treatments, recurrence and survival outcomes were analysed...
August 4, 2018: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
Elsaid Wasfy, Galal Elkassas, Sally Elnawasany, Kariman Elkasrawy, Sherief Abd-Elsalam, Shaimaa Soliman, Rehab Badawi
Background& Aims: Esophageal varices (EV) are a major complication of portal hypertension in cirrhotic patients. Screening is essential for all patients with cirrhosis. Performing non-invasive methods for screening is a cost-effective and time-saving measure. The aim of this work is to evaluate whether insulin resistance (IR) assessed by HOMA-IR score can predict the presence of EV or not. METHODS: This cross-sectional study was carried out on sixty Egyptian cirrhotic HCV patients divided into 3 groups: Group I: 20 cirrhotic patients without esophageal varices, Group II: 20 cirrhotic patients, with small esophageal varices and Group III: 20 cirrhotic patients with large esophageal varices...
August 3, 2018: Endocrine, Metabolic & Immune Disorders Drug Targets
George Boon-Bee Goh, Philip R Schauer, Arthur J McCullough
With the ever increasing global obesity pandemic, clinical burden from obesity related complications are anticipated in parallel. Bariatric surgery, a treatment approved for weight loss in morbidly obese patients, has reported to be associated with good outcomes, such as reversal of type two diabetes mellitus and reducing all-cause mortality on a long term basis. However, complications from bariatric surgery have similarly been reported. In particular, with the onslaught of non-alcoholic fatty liver disease (NAFLD) epidemic, in associated with obesity and metabolic syndrome, there is increasing prevalence of NAFLD related liver cirrhosis, which potentially connotes more risk of specific complications for surgery...
July 28, 2018: World Journal of Gastroenterology: WJG
Raj Vuppalanchi, Karan Mathur, Maximillian Pyko, Niharika Samala, Naga Chalasani
Non-cirrhotic portal hypertension (NCPH) is often a diagnostic challenge due to signs and symptoms of portal hypertension that overlap with cirrhosis. The etiology of NCPH is broadly classified as prehepatic, hepatic (pre-sinusoidal and sinusoidal) and post-hepatic.1 Some common etiologies of NCPH encountered in clinical practice include portal vein thrombosis (prehepatic) and nodular regenerative hyperplasia (NRH) (hepatic). This article is protected by copyright. All rights reserved.
July 17, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Michael Sørensen, Lars P Larsen, Gerda E Villadsen, Niels K Aagaard, Henning Grønbæk, Susanne Keiding, Hendrik Vilstrup
BACKGROUND: Presinusoidal portal hypertension is a clinically important cause of gastric and gastroesophageal varices. Whereas β-blockers have an established prophylactic role against bleeding from esophageal and gastric varices in portal hypertension due to cirrhosis, the effect on presinusoidal portal hypertension is unknown. AIMS: To evaluate the hemodynamic effect of β-blockers in non-cirrhotic patients with presinusoidal portal hypertension. METHODS: We measured the blood pressure gradient from spleen pulp to free hepatic vein in 12 patients with presinusoidal portal hypertension by combined hepatic vein catheterization and spleen pulp puncture while on and off β-blocker treatment (random sequence)...
July 12, 2018: Digestive Diseases and Sciences
C Y He, Y Lyu, H Chen, H B Liu, Q H Wang, J H Fan, B H Luo, T L Yu, X L Yuan, J Tie, J Niu, W G Guo, Z X Yin, G H Han
No abstract text is available yet for this article.
April 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
X L Qi
The non-invasive era of portal hypertension in cirrhosis is approaching. We should seize the opportunity: then do learn to follow the recommended international guidelines for emerging non-invasive technologies and systematically utilize case resources of our country's for clinical verification; Secondly, we should pay attention to the cross-theory innovation of the middle level discipline in the process of technology development, and standardize the design and clinical registration in accordance with international diagnostic testing standards; Finally, a non-invasive technique for the treatment of cirrhotic portal hypertension was developed with a developmental perspective, enabling the transition from disease diagnosis and risk stratification to efficacy monitoring and prognosis prediction...
April 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
Lucas Souto Nacif, Denise C Paranagua-Vezozzo, Alina Matsuda, Venancio Avancini Ferreira Alves, Flair J Carrilho, Alberto Queiroz Farias, Luiz Carneiro D'Albuquerque, Wellington Andraus
BACKGROUND: Liver elastography have been reported in hepatocellular carcinoma (HCC) with higher values; however, it is unclear to identify morbimortality risk on liver transplantation waiting list. AIM: To assess liver stiffness, ultrasound and clinical findings in cirrhotic patients with and without HCC on screening for liver transplant and compare the morbimortality risk with elastography and MELD score. METHOD: Patients with cirrhosis and HCC on screening for liver transplant were enrolled with clinical, radiological and laboratory assessments, and transient elastography...
June 21, 2018: Arquivos Brasileiros de Cirurgia Digestiva: ABCD, Brazilian Archives of Digestive Surgery
Jonel Trebicka
No abstract text is available yet for this article.
August 2018: Digestive and Liver Disease
Delphine Weil, Jean-Paul Pais de Barros, Guillaume Mourey, Caroline Laheurte, Benoit Cypriani, Nicolas Badet, Eric Delabrousse, Emilie Grandclément, Vincent Di Martino, Philippe Saas, Laurent Lagrost, Thierry Thévenot
BACKGROUND & AIMS: The quantification of lipopolysaccharide (LPS) in biological fluids is challenging. We aimed to measure plasma LPS concentration using a new method of direct quantification of 3-hydroxymyristate (3-HM), a lipid component of LPS, and to evaluate correlations between 3-HM and markers of liver function, endothelial activation, portal hypertension and enterocyte damage. METHODS: Plasma from 90 noninfected cirrhotic patients (30 Child-Pugh [CP]-A, 30 CP-B, 30 CP-C) was prospectively collected...
June 22, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Philipp Schwabl, Ksenia Brusilovskaya, Paul Supper, David Bauer, Philipp Königshofer, Florian Riedl, Hubert Hayden, Claudia Daniela Fuchs, Judith Stift, Georg Oberhuber, Stefan Aschauer, Diana Bonderman, Thorsten Gnad, Alexander Pfeifer, Frank Erhard Uschner, Jonel Trebicka, Nataliya Rohr-Udilova, Bruno Karl Podesser, Markus Peck-Radosavljevic, Michael Trauner, Thomas Reiberger
In cirrhotic patients, portal hypertension (PHT) deteriorates survival, yet treatment options are limited. A major contributor to increased intrahepatic vasoconstriction in PHT is dysfunctional nitric-oxide signaling. Soluble guanylate cyclase (sGC) is the receptor of nitric-oxide and can be stimulated by riociguat. Riociguat is approved for pulmonary hypertension but has not been studied in liver cirrhosis. In this study we assessed the effects of riociguat on PHT and liver fibrosis in cholestatic (bile duct ligation, BDL) and toxic (carbon-tetrachloride, CCl4) rat models...
June 19, 2018: Scientific Reports
Cristina Stasi, Caterina Silvestri, Roberto Berni, Maurizia Rossana Brunetto, Anna Linda Zignego, Cristina Orsini, Stefano Milani, Liana Ricciardi, Andrea De Luca, Pierluigi Blanc, Cesira Nencioni, Donatella Aquilini, Alessandro Bartoloni, Giampaolo Bresci, Santino Marchi, Franco Filipponi, Piero Colombatto, Paolo Forte, Andrea Galli, Sauro Luchi, Silvia Chigiotti, Alessandro Nerli, Giampaolo Corti, Rodolfo Sacco, Paola Carrai, Angelo Ricchiuti, Massimo Giusti, Paolo Almi, Andrea Cozzi, Silvia Carloppi, Giacomo Laffi, Fabio Voller, Francesco Cipriani
BACKGROUND: Recent introduction of direct antiviral agents (DAAs) has completely changed the scenario regarding hepatitis C virus (HCV) treatment. Certain countries' economic health programs prioritize DAAs according to specific clinical features of HCV-infected patients. The aim of this study was to define epidemiological, demographic and clinical characteristics of HCV-infected patients in the Tuscany region of central Italy. METHODS: We enrolled HCV patients with chronic viral hepatitis who were referred to the outpatient services of 16 hospitals in Tuscany from 1 January 2015 to 31 December 2015...
June 26, 2018: Current Medical Research and Opinion
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"